PURPOSE: Chronic central serous chorioretinopathy (CSC) is a vision-threatening eye disease for which there is still no approved treatment. Recent studies suggest that the corticosteroid pathway in the choroid is implicated in CSC pathogenesis, and that therapy with the aldosterone antagonist eplerenone improves clinical outcomes. However, there is still little clinical data to support this hypothesis. We performed a retrospective chart review to further investigate the clinical value of eplerenone treatment in patients with chronic CSC and to identify possible response predictors. METHODS: Twenty-four patients with chronic CSC resistant to conventional therapy over at least 4 months were included in this retrospective study. Patients were initially treated with 25 mg/day of eplerenone administered orally for 1 week, followed by a sustained daily dose of 50 mg. The primary outcome measure was percentage of eyes achieving complete resolution of subretinal fluid (SRF), recorded by spectral domain optical coherence tomography (SD-OCT). Secondary outcomes included changes in central macular thickness (CMT) and best-corrected visual acuity (BCVA). Baseline SD-OCT images were also evaluated as possible predictors of treatment response. RESULTS: Twenty-nine percent of patients experienced complete resolution of SRF after a median of 106 days of treatment, while 33 % of patients showed a transient initial decrease in SRF, and 25 % failed to respond to treatment. Treatment had to be stopped in 13 % of patients because of adverse effects of the eplerenone treatment. In the study population, CMT decreased from 342 to 275 μm after treatment, which was associated with a modest improvement in mean BCVA from 0.35 to 0.3 logMar. The integrity of the ellipsoid zone and the retinal pigment epithelium (RPE) at baseline were associated with a tendency towards a favourable visual outcome. CONCLUSION: This study confirms the proposed clinical value of eplerenone for treating patients with therapy-resistant CSC. However, patients presenting widespread RPE changes are less likely to benefit from eplerenone treatment, which may argue for an earlier intervention. Larger studies are needed to characterise patient subgroups that may benefit the most from eplerenone treatment.
PURPOSE:Chronic central serous chorioretinopathy (CSC) is a vision-threatening eye disease for which there is still no approved treatment. Recent studies suggest that the corticosteroid pathway in the choroid is implicated in CSC pathogenesis, and that therapy with the aldosterone antagonist eplerenone improves clinical outcomes. However, there is still little clinical data to support this hypothesis. We performed a retrospective chart review to further investigate the clinical value of eplerenone treatment in patients with chronic CSC and to identify possible response predictors. METHODS: Twenty-four patients with chronic CSC resistant to conventional therapy over at least 4 months were included in this retrospective study. Patients were initially treated with 25 mg/day of eplerenone administered orally for 1 week, followed by a sustained daily dose of 50 mg. The primary outcome measure was percentage of eyes achieving complete resolution of subretinal fluid (SRF), recorded by spectral domain optical coherence tomography (SD-OCT). Secondary outcomes included changes in central macular thickness (CMT) and best-corrected visual acuity (BCVA). Baseline SD-OCT images were also evaluated as possible predictors of treatment response. RESULTS: Twenty-nine percent of patients experienced complete resolution of SRF after a median of 106 days of treatment, while 33 % of patients showed a transient initial decrease in SRF, and 25 % failed to respond to treatment. Treatment had to be stopped in 13 % of patients because of adverse effects of the eplerenone treatment. In the study population, CMT decreased from 342 to 275 μm after treatment, which was associated with a modest improvement in mean BCVA from 0.35 to 0.3 logMar. The integrity of the ellipsoid zone and the retinal pigment epithelium (RPE) at baseline were associated with a tendency towards a favourable visual outcome. CONCLUSION: This study confirms the proposed clinical value of eplerenone for treating patients with therapy-resistant CSC. However, patients presenting widespread RPE changes are less likely to benefit from eplerenone treatment, which may argue for an earlier intervention. Larger studies are needed to characterise patient subgroups that may benefit the most from eplerenone treatment.
Entities:
Keywords:
Central macular thickness; Central serous chorioretinopathy; Eplerenone; Mineralocorticoid antagonist; Subretinal fluid
Authors: David A Salz; John D Pitcher; Jason Hsu; Carl D Regillo; Mitchell S Fineman; Kevin S Elliott; James F Vander; David H Fischer; Marc J Spirn Journal: Ophthalmic Surg Lasers Imaging Retina Date: 2015-04 Impact factor: 1.300
Authors: Eiko K de Jong; Myrte B Breukink; Rosa L Schellevis; Bjorn Bakker; Jacqueline K Mohr; Sascha Fauser; Jan E E Keunen; Carel B Hoyng; Anneke I den Hollander; Camiel J F Boon Journal: Ophthalmology Date: 2014-11-06 Impact factor: 12.079
Authors: Eric K Chin; David Rp Almeida; C Nathaniel Roybal; Philip I Niles; Karen M Gehrs; Elliott H Sohn; H Culver Boldt; Stephen R Russell; James C Folk Journal: Clin Ophthalmol Date: 2015-08-11
Authors: R Sacconi; G Baldin; A Carnevali; L Querques; A Rabiolo; G Marchini; F Bandello; G Querques Journal: Eye (Lond) Date: 2018-01-05 Impact factor: 3.775
Authors: Elon H C van Dijk; Rosa L Schellevis; Maaike G J M van Bergen; Myrte B Breukink; Lebriz Altay; Paula Scholz; Sascha Fauser; Onno C Meijer; Carel B Hoyng; Anneke I den Hollander; Camiel J F Boon; Eiko K de Jong Journal: JAMA Ophthalmol Date: 2017-05-01 Impact factor: 7.389
Authors: Thomas J van Rijssen; Danial Mohabati; Greet Dijkman; Thomas Theelen; Eiko K de Jong; Elon H C van Dijk; Camiel J F Boon Journal: PLoS One Date: 2018-08-24 Impact factor: 3.240
Authors: Daren Hanumunthadu; Anna C S Tan; Sumit Randhir Singh; Niroj Kumar Sahu; Jay Chhablani Journal: Indian J Ophthalmol Date: 2018-12 Impact factor: 1.848